Showing results (891-900 of 1,376) with videos related to

Sort By:
Pageof 138
Neuro-Oncology Advances|August 4, 2020
Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progressionMylan R Blomquist, Shannon Fortin Ensign, Fulvio D'Angelo, et al.
Neuro-Oncology Advances|August 4, 2020
Impact of the Patient Protection and Affordable Care Act on 1-year survival in glioblastoma patientsNuriel Moghavem, Debora L Oh, Eduardo J Santiago-Rodríguez, et al.
Neuro-Oncology Advances|July 10, 2020
Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatmentSylvain Portet, Rania Naoufal, Gaëlle Tachon, et al.
Neuro-Oncology Advances|July 10, 2020
Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine modelsMaria J Sambade, Amanda E D Van Swearingen, Marni B McClure, et al.
Neuro-Oncology Advances|July 10, 2020
Current status of PET imaging in neuro-oncologyNorbert Galldiks, Philipp Lohmann, Nathalie L Albert, et al.
Neuro-Oncology Advances|July 10, 2020
The effect of brain metastasis location on clinical outcomes: A review of the literaturePragnan Kancharla, Alexander Ivanov, Susie Chan, et al.
Neuro-Oncology Advances|July 10, 2020
The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastomaVirginie Neirinckx, Ann-Christin Hau, Anne Schuster, et al.
Neuro-Oncology Advances|July 10, 2020
Identification of shared genomic aberrations between angiomatous and microcystic meningiomasYasuhiro Kuroi, Hiroyuki Akagawa, Makoto Shibuya, et al.
Neuro-Oncology Advances|July 10, 2020
The impact of host immune cells on the development of neurofibromatosis type 1: The abnormal immune system provides an immune microenvironment for tumorigenesisCheng-Jiang Wei, Shu-Chen Gu, Jie-Yi Ren, et al.
Neuro-Oncology Advances|July 10, 2020
A phase III double-blind placebo-controlled randomized study of dexamphetamine sulfate for fatigue in primary brain tumors patients: An ANOCEF trial (DXA)Florence Laigle-Donadey, François Ducray, Matthieu Boone, et al.
Pageof 138